Olaparib; Oliceridine; Omaveloxolone; Ombitasvir; Omeprazole; Ondansetron Liver disease, active or history ofUse with caution. May make these
Olaparib; Oliceridine; Omaveloxolone; Omeprazole; Osimertinib; Ospemifene Liver diseaseUse with caution. May make these conditions worse. Kidney
This case report highlights the need for close monitoring of liver tests while on olaparib and that the diagnosis of IM-DILI and prompt initiation of corticosteroids should be considered if an acute liver injury develops.
Olaparib therapy is associated with a low rate of transient elevations in serum aminotransferase during therapy and has not been linked to instances of clinically apparent liver injury. Sections OVERVIEW
) as a liver FDA approves olaparib with abiraterone and prednisone (or prednisolone) for BRCA-mutated metastatic castration-resistant prostate cancer
Olaparib is metabolized in the liver largely through the CYP 3A4 pathway and liver injury may be related to production of a toxic intermediate. Because it is a substrate for CYP 3A4, olaparib is susceptible to drug-drug interactions with agents that inhibit or induce hepatic CYP 3A activity.
We were able to catch this early and prevent harm from Drug Induced Liver Injury. Olaparib Olaratumab Olmesartan Omacetaxine Omadacycline Omalizumab
We report the first case in the United States of an acute and severe liver injury with associated jaundice and liver synthetic dysfunction secondary to olaparib. The liver injury was resolved with drug cessation and treatment with prednisone taper.
A Case of Immune-Mediated Liver Injury Induced by Olaparib. Carmen Ricci. Hepatology
Comments